Alpha-emitter anticancer agents
Algeta developed Xofigo® (radium-223 dichloride), a first-in-class, targeted alpha-pharmaceutical that was approved by the US FDA and European EMA for treatment of patients with symptomatic bone metastases secondary to castration-resistant prostate cancer.
CEO Andrew Kay
Advent invested in the Series A in 2005. Algeta listed on the Oslo Stock exchange in March 2007 and was acquired by Bayer in 2014 for $2.9B.
Bayer commences voluntary cash offer to acquire the entire issued share capital of Algeta
Press Release. Oslo, Norway, 20 January, 2014 - Algeta ASA ("Algeta"; OSE: ALGETA) today announced that Aviator Acquisition AS, a wholly-owned subsidiary of Bayer Nordic SE, has commenced the…Read More
The Board of Directors of Algeta ASA unanimously recommends voluntary cash offer from Bayer to acquire the entire issued share capital of Algeta
Press Release. Not intended for US media Offer at NOK 362 per Algeta share, in cash, valuing the total share capital of Algeta at approximately NOK 17.6 billion (USD…Read More
Algeta announces that Xofigo® (radium-223 dichloride) has been approved by the US FDA
Press Release. New treatment for castration-resistant prostate cancer (CRPC) patients with bone metastases Xofigo shown in a pivotal phase III trial to significantly improve overall survival Algeta to host…Read More